Literature DB >> 1915462

Humoral immune response against contractile proteins (actin and myosin) during cardiovascular disease.

I K De Scheerder1, M De Buyzere, J Delanghe, A Maas, D L Clement, R Wieme.   

Abstract

Sensitive and highly specific ELISA assays were developed to determine humoral immune response against actin and myosin in 122 patients suffering from various cardiovascular diseases: acute viral myocarditis (n = 10, MYO), acute myocardial infarction (n = 28, AMI), valve surgery (n = 35, VALVE), coronary bypass surgery (n = 35, CABG), and peripheral vascular surgery (n = 14, VASC). Anti-actin and anti-myosin antibodies were determined on admission and serially during a period of 90 days. Anti-actin and anti-myosin immune response (IgG, IgM) was expressed comparing absorbance of the patients' serum with a reference serum. In the different patient groups significantly (P less than 0.01) higher anti-actin and anti-myosin antibody concentrations were found on admission compared with age-matched control groups. During follow-up, all patient groups except the vascular surgery group showed a significant immune response against actin and myosin, with an immune response ratio (peak/admission) for AMA IgG and IgM respectively of 2.12 and 2.40 in the VALVE group, 1.30 and 1.99 in the CABG group, 1.42 and 1.48 in the AMI group and 1.66 and 1.25 in the MYO group; and for AAA IgG and IgM respectively of 1.57 and 3.00 in the VALVE group, 1.54 and 1.64 in the CABG group, 1.25 and 1.07 in the AMI group, and 1.42 and 1.42 in the MYO group. A significant correlation between pre-cardiac injury and peak post-cardiac injury anti-myosin and anti-actin autoantibody levels could be demonstrated suggesting that pre-injury sensitization to these antigens plays an important role in evoking post-cardiac injury immune response.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1915462     DOI: 10.1093/eurheartj/12.suppl_d.88

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  5 in total

1.  Cardiac autoantibodies in dilated cardiomyopathy become undetectable with disease progression.

Authors:  A L Caforio; J H Goldman; M K Baig; A J Haven; L Dalla Libera; P J Keeling; W J McKenna
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

2.  Cardiac myosin autoimmunity in acute Chagas' heart disease.

Authors:  J S Leon; L M Godsel; K Wang; D M Engman
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

3.  Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases.

Authors:  C A von Mühlen; E K Chan; C L Peebles; H Imai; K Kiyosawa; E M Tan
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

4.  Branched chain α-ketoacid dehydrogenase kinase 111-130, a T cell epitope that induces both autoimmune myocarditis and hepatitis in A/J mice.

Authors:  Bharathi Krishnan; Chandirasegaran Massilamany; Rakesh H Basavalingappa; Arunakumar Gangaplara; Guobin Kang; Qingsheng Li; Francisco A Uzal; Jennifer L Strande; Gustavo A Delhon; Jean-Jack Riethoven; David Steffen; Jay Reddy
Journal:  Immun Inflamm Dis       Date:  2017-06-09

5.  Rethinking Molecular Mimicry in Rheumatic Heart Disease and Autoimmune Myocarditis: Laminin, Collagen IV, CAR, and B1AR as Initial Targets of Disease.

Authors:  Robert Root-Bernstein
Journal:  Front Pediatr       Date:  2014-08-19       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.